In addition, CRIP1 can promote proteasome inhibitor resistance through the CRIP1/USP7/PA200 axis [35], which can inhibit the sensitivity of tumor cells to chemotherapeutic drugs such as fluorouracil and gemcitabine to some extent, thus becoming a potential target for immunotherapy. This evidence concerns the gene CRIP1 and neoplasm.